A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika

Molecular Therapy

Volumn 26, Issue 10, 2018, Pages 2507-2522

  Erasmus, Jesse H ^a   Khandhar, Amit P ^a   Guderian, Jeff ^a   Granger, Brian ^a   Archer, Jacob ^a   Archer, Michelle ^a   Gage, Emily ^a,b   Fuerte Stone, Jasmine ^a   Larson, Elise ^a   Lin, Susan ^a   Kramer, Ryan ^a   Coler, Rhea N ^a,b,c   Fox, Christopher B ^a   Stinchcomb, Dan T ^a   Reed, Steven G ^a,b   Van Hoeven, Neal ^a,b,c  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PAI Life Sciences   (United States)

Author keywords

alphavirus; emulsion; flavivirus; nanostructured lipid carrier; non viral delivery; replicon; RNA delivery; RNA vaccines; Zika virus

Indexed keywords

NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RNA; ZIKA VIRUS VACCINE; LIPID; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INCUBATION TIME; LOW DRUG DOSE; MOUSE; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; SEROCONVERSION; SINGLE DRUG DOSE; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; ZIKA FEVER; ZIKA VIRUS; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; IMMUNOLOGY; PATHOGENICITY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; MICE; NANOPARTICLES; RNA, VIRAL; VIRUS REPLICATION; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85050868844     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2018.07.010     Document Type: Article

References (65)

1. Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P.L., Direct gene transfer into mouse muscle in vivo. Science 247 (1990), 1465–1468.
2. Kaczmarek, J.C., Kowalski, P.S., Anderson, D.G., Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med., 9, 2017, 60.
3. DeFrancesco, L., The ‘anti-hype’ vaccine. Nat. Biotechnol. 35 (2017), 193–197.
4. Hekele, A., Bertholet, S., Archer, J., Gibson, D.G., Palladino, G., Brito, L.A., Otten, G.R., Brazzoli, M., Buccato, S., Bonci, A., et al. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect., 2, 2013, e52.
5. Ball, R.L., Bajaj, P., Whitehead, K.A., Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int. J. Nanomedicine 12 (2016), 305–315.
6. Charlton Hume, H.K., Lua, L.H.L., Platform technologies for modern vaccine manufacturing. Vaccine 35:35 Pt A (2017), 4480–4485.
7. Plotkin, S., Robinson, J.M., Cunningham, G., Iqbal, R., Larsen, S., The complexity and cost of vaccine manufacturing - An overview. Vaccine 35 (2017), 4064–4071.
8. Myhr, A.I., DNA Vaccines: Regulatory Considerations and Safety Aspects. Curr. Issues Mol. Biol. 22 (2017), 79–88.
9. Lechardeur, D., Lukacs, G.L., Nucleocytoplasmic transport of plasmid DNA: a perilous journey from the cytoplasm to the nucleus. Hum. Gene Ther. 17 (2006), 882–889.
10. Bogers, W.M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E.J., Davis, D., Ulmer, J.B., Brito, L.A., Cu, Y., Banerjee, K., et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J. Infect. Dis. 211 (2015), 947–955.
11. Geall, A.J., Verma, A., Otten, G.R., Shaw, C.A., Hekele, A., Banerjee, K., Cu, Y., Beard, C.W., Brito, L.A., Krucker, T., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 109 (2012), 14604–14609.
12. Petsch, B., Schnee, M., Vogel, A.B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.J., Stitz, L., Kramps, T., Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30 (2012), 1210–1216.
13. Li, J., He, Y., Wang, W., Wu, C., Hong, C., Hammond, P.T., Polyamine-Mediated Stoichiometric Assembly of Ribonucleoproteins for Enhanced mRNA Delivery. Angew. Chem. Int. Ed. Engl. 56 (2017), 13709–13712.
14. Lehto, T., Ezzat, K., Wood, M.J.A., El Andaloussi, S., Peptides for nucleic acid delivery. Adv. Drug Deliv. Rev. 106:Pt A (2016), 172–182.
15. Schott, J.W., Morgan, M., Galla, M., Schambach, A., Viral and Synthetic RNA Vector Technologies and Applications. Mol. Ther. 24 (2016), 1513–1527.
16. Barefoot, B., Thornburg, N.J., Barouch, D.H., Yu, J.S., Sample, C., Johnston, R.E., Liao, H.X., Kepler, T.B., Haynes, B.F., Ramsburg, E., Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26 (2008), 6108–6118.
17. Liao, F., Xu, H., Torrey, N., Road, P., Jolla, L., Lipid Nanoparticles for Gene Delivery. Adv. Genet. 2 (2015), 1–21.
18. Kau, K.J., Dorkin, J.R., Yang, J.H., Heartlein, M.W., DeRosa, F., Mir, F.F., Fenton, O.S., Anderson, D.G., Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett 15 (2015), 7300–7306.
19. Brito, L.A., Chan, M., Shaw, C.A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G.R., Beard, C.W., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22 (2014), 2118–2129.
20. Dwarki, V.J., Malone, R.W., Verma, I.M., Cationic liposome-mediated RNA transfection. Methods Enzymol. 217 (1993), 644–654.
21. Foy, B.D., Kobylinski, K.C., Chilson Foy, J.L., Blitvich, B.J., Travassos da Rosa, A., Haddow, A.D., Lanciotti, R.S., Tesh, R.B., Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 17 (2011), 880–882.
22. Pinto-Díaz, C.A., Rodríguez, Y., Monsalve, D.M., Acosta-Ampudia, Y., Molano-González, N., Anaya, J.M., Ramírez-Santana, C., Autoimmunity in Guillain-Barré syndrome associated with Zika virus infection and beyond. Autoimmun. Rev. 16 (2017), 327–334.
23. Anaya, J.-M., Rodríguez, Y., Monsalve, D.M., Vega, D., Ojeda, E., González-Bravo, D., Rodríguez-Jiménez, M., Pinto-Díaz, C.A., Chaparro, P., Gunturiz, M.L., et al. A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. J. Autoimmun. 77 (2017), 123–138.
24. Cugola, F.R., Fernandes, I.R., Russo, F.B., Freitas, B.C., Dias, J.L., Guimarães, K.P., Benazzato, C., Almeida, N., Pignatari, G.C., Romero, S., et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534 (2016), 267–271.
25. Rasmussen, S.A., Jamieson, D.J., Honein, M.A., Petersen, L.R., Zika virus and birth defects—reviewing the evidence for causality. N. Engl. J. Med. 374 (2016), 1981–1987.
26. Pradhan, D., Yadav, M., Verma, R., Khan, N.S., Jena, L., Jain, A.K., Discovery of T-cell Driven Subunit Vaccines from Zika Virus Genome: An Immunoinformatics Approach. Interdiscip. Sci. 9 (2017), 468–477.
27. To, A., Medina, L.O., Mfuh, K.O., Lieberman, M.M., Wong, T.A.S., Namekar, M., Nakano, E., Lai, C.Y., Kumar, M., Nerurkar, V.R., Lehrer, A.T., Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice. MSphere, 3, 2018 e00576–e17.
28. Modjarrad, K., Lin, L., George, S.L., Stephenson, K.E., Eckels, K.H., De La Barrera, R.A., Jarman, R.G., Sondergaard, E., Tennant, J., Ansel, J.L., et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391 (2018), 563–571.
29. Abbink, P., Larocca, R.A., De La Barrera, R.A., Bricault, C.A., Moseley, E.T., Boyd, M., Krilova, M., Li, Z., Ng'ang'a, D., Nanayakkara, O., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353 (2016), 1129–1132.
30. Xie, X., Yang, Y., Muruato, A.E., Zou, J., Shan, C., Nunes, B.T., Medeiros, D.B., Vasconcelos, P.F., Weaver, S.C., Rossi, S.L., Shi, P.Y., Understanding zika virus stability and developing a chimeric vaccine through functional analysis. MBio 8 (2017), 1–14.
31. Shan, C., Muruato, A.E., Nunes, B.T.D., Luo, H., Xie, X., Medeiros, D.B.A., Wakamiya, M., Tesh, R.B., Barrett, A.D., Wang, T., et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat. Med. 23 (2017), 763–767.
32. Dowd, K.A., Ko, S.Y., Morabito, K.M., Yang, E.S., Pelc, R.S., DeMaso, C.R., Castilho, L.R., Abbink, P., Boyd, M., Nityanandam, R., et al. Rapid development of a DNA vaccine for Zika virus. Science 354 (2016), 237–240.
33. Larocca, R.A., Abbink, P., Peron, J.P., Zanotto, P.M., Iampietro, M.J., Badamchi-Zadeh, A., Boyd, M., Ng'ang'a, D., Kirilova, M., Nityanandam, R., et al. Vaccine protection against Zika virus from Brazil. Nature 536 (2016), 474–478.
34. Muthumani, K., Griffin, B.D., Agarwal, S., Kudchodkar, S.B., Reuschel, E.L., Choi, H., Kraynyak, K.A., Duperret, E.K., Keaton, A.A., Chung, C., et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines, 1, 2016, 16021.
35. Pardi, N., Hogan, M.J., Pelc, R.S., Muramatsu, H., Andersen, H., DeMaso, C.R., Dowd, K.A., Sutherland, L.L., Scearce, R.M., Parks, R., et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543 (2017), 248–251.
36. Richner, J.M., Jagger, B.W., Shan, C., Fontes, C.R., Dowd, K.A., Cao, B., Himansu, S., Caine, E.A., Nunes, B.T.D., Medeiros, D.B.A., et al. Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell 170 (2017), 273–283.e12.
37. Richner, J.M., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J.M., Julander, J.G., Tang, W.W., Shresta, S., Pierson, T.C., et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168 (2017), 1114–1125.e10.
38. Müller, R.H., Alexiev, U., Sinambela, P., Keck, C.M., Nanostructured lipid carriers (NLC): the second generation of solid lipid nanoparticles. Dragicevic, N., Maibach, H.I., (eds.) Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Nanocarriers, 2016, Springer, 161–185.
39. Ljungberg, K., Liljeström, P., Self-replicating alphavirus RNA vaccines. Expert Rev. Vaccines 14 (2015), 177–194.
40. Baronti, C., Piorkowski, G., Charrel, R.N., Boubis, L., Leparc-Goffart, I., de Lamballerie, X., Complete coding sequence of zika virus from a French polynesia outbreak in 2013. Genome Announc. 2 (2014), e00500–e00514.
41. Chang, G.J.J., Hunt, A.R., Holmes, D.A., Springfield, T., Chiueh, T.S., Roehrig, J.T., Gubler, D.J., Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306 (2003), 170–180.
42. Calabro, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., De Gregorio, E., O'Hagan, D.T., Baudner, B., Seubert, A., The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31 (2013), 3363–3369.
43. Calabro, S., Tortoli, M., Baudner, B.C., Pacitto, A., Cortese, M., O'Hagan, D.T., De Gregorio, E., Seubert, A., Wack, A., Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29 (2011), 1812–1823.
44. Seubert, A., Monaci, E., Pizza, M., O'Hagan, D.T., Wack, A., The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180 (2008), 5402–5412.
45. Rossi, S.L., Tesh, R.B., Azar, S.R., Muruato, A.E., Hanley, K.A., Auguste, A.J., Langsjoen, R.M., Paessler, S., Vasilakis, N., Weaver, S.C., Characterization of a Novel Murine Model to Study Zika Virus. Am. J. Trop. Med. Hyg. 94 (2016), 1362–1369.
46. Smith, D.R., Hollidge, B., Daye, S., Zeng, X., Blancett, C., Kuszpit, K., Bocan, T., Koehler, J.W., Coyne, S., Minogue, T., et al. Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. PLoS Negl. Trop. Dis., 11, 2017, e0005296.
47. Lv, H., Zhang, S., Wang, B., Cui, S., Yan, J., Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114 (2006), 100–109.
48. Desbien, A.L., Reed, S.J., Bailor, H.R., Dubois Cauwelaert, N., Laurance, J.D., Orr, M.T., Fox, C.B., Carter, D., Reed, S.G., Duthie, M.S., Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ. Eur. J. Immunol. 45 (2015), 407–417.
49. Wilhelmsen, C.L., Waag, D.M., Guinea pig abscess/hypersensitivity model for study of adverse vaccination reactions induced by use of Q fever vaccines. Comp. Med. 50 (2000), 374–378.
50. Maurer, T., Guinea pigs in hypersensitivity testing. Methods 41 (2007), 48–53.
51. Pepini, T., Pulichino, A.M., Carsillo, T., Carlson, A.L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J.C., Maruggi, G., Otten, G.R., Geall, A.J., et al. Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design. J. Immunol. 198 (2017), 4012–4024.
52. + T Cell Response During Primary Zika Virus Infection in Mice. Cell Host Microbe 21 (2017), 35–46.
53. Knudsen, M.L., Ljungberg, K., Kakoulidou, M., Kostic, L., Hallengärd, D., García-Arriaza, J., Merits, A., Esteban, M., Liljeström, P., Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. J. Virol. 88 (2014), 12438–12451.
54. Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D., Delivery materials for siRNA therapeutics. Nat. Mater. 12 (2013), 967–977.
55. Kanasty, R.L., Whitehead, K.A., Vegas, A.J., Anderson, D.G., Action and reaction: the biological response to siRNA and its delivery vehicles. Mol. Ther. 20 (2012), 513–524.
56. Rietwyk, S., Peer, D., Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano 11 (2017), 7572–7586.
57. Kim, T.W., Kim, Y.J., Chung, H., Kwon, I.C., Sung, H.C., Jeong, S.Y., The role of non-ionic surfactants on cationic lipid mediated gene transfer. J. Control. Release 82 (2002), 455–465.
58. Leitner, W.W., Hwang, L.N., deVeer, M.J., Zhou, A., Silverman, R.H., Williams, B.R., Dubensky, T.W., Ying, H., Restifo, N.P., Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9 (2003), 33–39.
59. Nguyen, D.N., Chen, S.C., Lu, J., Goldberg, M., Kim, P., Sprague, A., Novobrantseva, T., Sherman, J., Shulga-Morskaya, S., de Fougerolles, A., et al. Drug delivery-mediated control of RNA immunostimulation. Mol. Ther. 17 (2009), 1555–1562.
60. Nguyen, D.N., Mahon, K.P., Chikh, G., Kim, P., Chung, H., Vicari, A.P., Love, K.T., Goldberg, M., Chen, S., Krieg, A.M., et al. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc. Natl. Acad. Sci. USA 109 (2012), E797–E803.
61. Misquith, A., Fung, H.W., Dowling, Q.M., Guderian, J.A., Vedvick, T.S., Fox, C.B., In vitro evaluation of TLR4 agonist activity: formulation effects. Colloids Surf. B Biointerfaces 113 (2014), 312–319.
62. Pardi, N., Secreto, A.J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B.L., Tam, Y.K., et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun., 8, 2017, 14630.
63. Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L.M., et al. Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin. J. Virol. 90 (2015), 332–344.
64. Maruggi, G., Chiarot, E., Giovani, C., Buccato, S., Bonacci, S., Frigimelica, E., Margarit, I., Geall, A., Bensi, G., Maione, D., Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35 (2017), 361–368.
65. Beaty, B.J.J., Calisher, C.H.H., Shope, R.E.E., Arboviruses. Schmidt, N.J.J., Emmons, R.W.W., (eds.) Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 1989, American Public Health Association, 797–855.